This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
REDWOOD CITY, Calif., Jan. 27, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer, will speak at two upcoming investor conferences in February.
16th Annual BIO CEO and Investor Conference on February 10, 2014 at 10:30 am ET, being held in New York City at the Waldorf Astoria New York.
Leerink Swann 2014 Global Healthcare Conference on February 13, 2014 at 8:05 am ET being held in New York City at the Waldorf Astoria New York.
To access the live webcasts and subsequent archived recordings for each of these presentations, please visit OncoMed's website at
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells. OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, Anti-DLL4/Anti-VEGF bispecific and Anti-RSPO3, with Investigational New Drug filings planned for as early as 2014. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website:
CONTACT: Investor Contact:
Karen L. Bergman or
(650) 575-1509 or (415) 794-8662